- Home
- PVBC vs CHRS Comparison
PVBC vs CHRS Comparison
Compare PVBC & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVBC
- CHRS
- Stock Information
- Founded
- PVBC 1913
- CHRS 2010
- Country
- PVBC United States
- CHRS United States
- Employees
- PVBC N/A
- CHRS N/A
- Industry
- PVBC Major Banks
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PVBC Finance
- CHRS Health Care
- Exchange
- PVBC Nasdaq
- CHRS Nasdaq
- Market Cap
- PVBC 202.6M
- CHRS 84.2M
- IPO Year
- PVBC 2015
- CHRS 2014
- Fundamental
- Price
- PVBC $12.83
- CHRS $0.90
- Analyst Decision
- PVBC Hold
- CHRS Buy
- Analyst Count
- PVBC 1
- CHRS 3
- Target Price
- PVBC $12.50
- CHRS $4.68
- AVG Volume (30 Days)
- PVBC 251.0K
- CHRS 1.2M
- Earning Date
- PVBC 07-28-2025
- CHRS 08-07-2025
- Dividend Yield
- PVBC N/A
- CHRS N/A
- EPS Growth
- PVBC N/A
- CHRS N/A
- EPS
- PVBC 0.26
- CHRS N/A
- Revenue
- PVBC $50,244,000.00
- CHRS $272,251,000.00
- Revenue This Year
- PVBC $9.73
- CHRS N/A
- Revenue Next Year
- PVBC $4.87
- CHRS $106.56
- P/E Ratio
- PVBC $49.31
- CHRS N/A
- Revenue Growth
- PVBC N/A
- CHRS 19.87
- 52 Week Low
- PVBC $9.67
- CHRS $0.66
- 52 Week High
- PVBC $12.96
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PVBC 78.85
- CHRS 59.04
- Support Level
- PVBC $12.60
- CHRS $0.73
- Resistance Level
- PVBC $12.83
- CHRS $0.82
- Average True Range (ATR)
- PVBC 0.17
- CHRS 0.04
- MACD
- PVBC 0.03
- CHRS 0.02
- Stochastic Oscillator
- PVBC 91.15
- CHRS 88.02
About PVBC Provident Bancorp Inc. (MD)
Provident Bancorp Inc provides a range of banking products and services to small and medium-sized commercial customers. It attracts deposits from the general public and uses those funds to originate loans, commercial real estate, construction and land, and commercial business loans, and to invest in securities. The company lending activities include providing commercial real estate loans, multi-family residential real estate loans, commercial business loans, construction and land development loans, one-to four-family residential loans, home equity loans & lines of credit, and consumer loans.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.